Farmácia/Notícias da Indústria

“Challenge Trials” com SARS-CoV-2 são éticos? – “Um ensaio clínico realizado no Reino Unido está expondo deliberadamente participantes jovens e saudáveis ao SARS-CoV-2 para avaliar a inoculação viral necessária para produzir infecção e testar a eficácia de vacinas.”

8 Jun, 2021 | 10:27h

Are SARS-CoV-2 Human Challenge Trials Ethical? – JAMA Internal Medicine

Relacionado: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o assunto)

Comentário no Twitter

I am not convinced of #SARSCoV2 #ChallengeTrials. You should not pay volunteers. If things go wrong, there is no effective treatment. What will be learnt from mild disease, when you are interested in severe disease? #COVID19 #Covid #Corona #coronavirus https://t.co/JjXDJDfOl2

— Martin Michaelis (@MartMichaelis) June 8, 2021

Estudo randomizado: Em pacientes internados com Covid-19 e D-dímero elevado, a estratégia de anticoagulação em dose plena baseada em rivaroxabam (dose plena de heparinas em pacientes instáveis) + rivaroxabam até o dia 30 não foi melhor do que a anticoagulação profilática e aumentou o risco de sangramento.

7 Jun, 2021 | 10:33h

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet

Relacionado: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.

Comentário no Twitter

Thanks @CMichaelGibson. Another important contribution from the Brazilian Coalition team and investigators in Brazil. Our 6th trial completed in 12 months. Go coalition!!!! https://t.co/TDUr1RukuW

— Renato D Lopes (@RenatoDLopes1) June 4, 2021

Estudo mostra atividade reduzida de anticorpos neutralizantes, induzida pela vacina da Pfizer–BioNTech, contra as variantes de preocupação do SARS-CoV-2 B.1.617.2 (Delta) e B.1.351 (Beta).

7 Jun, 2021 | 10:31h

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet

Comentário: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute

Comentário no Twitter (fio – clique para saber mais)

“Immune escape” in #DeltaVariant. That’s the latest finding – that #B16172 is as bad for antibody neutralization as the Beta variant #B1351 from South Africa 🇿🇦. 1st dose alone very small effect— 2 doses needed, but weakest against Delta. Let’s walk through evidence 🧵 #COVID19 https://t.co/GurgkNVgiY pic.twitter.com/o0s9WIudCW

— Eric Feigl-Ding (@DrEricDing) June 5, 2021

6 meses de vacinas contra COVID: o que 1,7 bilhão de doses ensinaram aos cientistas.

7 Jun, 2021 | 10:30h

Six months of COVID vaccines: what 1.7 billion doses have taught scientists – Nature

Ver também: Coronavirus (COVID-19) Vaccinations – Our World in Data

Comentário relacionado no Twitter

• To administer the first half a billion vaccines took 113 days
• The second half a billion 30 days
• The third half a billion 23 days
• And the fourth half a billion were administered in the last 16 days

We keep on counting on @OurWorldInData here: https://t.co/7lOyDamxxx pic.twitter.com/Pg7OPJxliI

— Max Roser (@MaxCRoser) June 4, 2021

Aprovação da vacina CoronaVac pela OMS será crucial na contenção da pandemia.

7 Jun, 2021 | 10:29h

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic – Nature

Relacionado: WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations E Brazilian town experiment shows mass vaccination can wipe out COVID-19.

Relato de caso: Tratamento bem-sucedido da trombocitopenia imune protrombótica induzida por vacina (VIPIT – vaccine-induced prothrombotic immune thrombocytopenia).

7 Jun, 2021 | 10:28h

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) – Journal of Thrombosis and Haemostasis

Comentário: COVID-19 vaccination: Thrombosis can be prevented by prompt treatment, researchers report – Medical University of Vienna

Perspectiva | As estatinas poderiam fazer mais do que baixar o colesterol em pacientes com COVID-19? – “Não comece, não pare.”

7 Jun, 2021 | 10:22h

Could Statins Do More Than Lower Cholesterol in Patients With COVID-19? – JAMA

M-A: Ácido tranexâmico pré-hospitalar reduz a mortalidade em pacientes com trauma e sangramento ativo sem aumentar o risco de tromboembolismo venoso.

7 Jun, 2021 | 10:11h

The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis – Journal of Trauma and Acute Care Surgery (link para o resumo – $ para o texto completo)

Comentário: Prehospital TXA for Trauma – Meta-analysis – JournalFeed

Mais um estudo mostra alta frequência de uso de antibióticos em pacientes hospitalizados com Covid-19 (85,2%), apesar das baixas taxas de confirmação de infecções bacterianas secundárias.

4 Jun, 2021 | 08:27h

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study – The Lancet Microbe

Comentários: Very high use of antibiotics in COVID-19 treatment could be reduced – University of Glasgow E More evidence of frequent antibiotic use noted in COVID patients – CIDRAP E Covid-19: Antimicrobial use was high during first wave despite bacterial co-infections being rare, study finds – The BMJ

Relacionado: Many hospitalized Covid-19 patients are given antibiotics. That’s a problem – STAT

Comentário no Twitter (fio – clique para saber mais)

Our paper on co-infections, secondary infections & antimicrobial use in patients hospitalised with #COVID19 in UK during the 1st wave is out in @LancetMicrobe!@ISARIC1 @CCPUKstudy @CVRinfo @UofGlasgow @EdinburghUni @LivUni @imperialcollege https://t.co/QYU1B2Eyup

A🧵

— Antonia Ho (@DrToniHo) June 3, 2021

Estudo randomizado: Profilaxia pós-exposição com banlanivimabe reduziu a incidência de Covid-19 entre residentes e equipe de enfermagem de casas de repouso.

4 Jun, 2021 | 08:26h

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial – JAMA

Editorial: Bamlanivimab for Prevention of COVID-19